Jlohr Brain Health
  • Home
  • About Us
  • Brain Health Diagnoses
  • Resources on this Site
    • Overviews: 9 Aspects of this Diagnoses
    • Drug Discount Services
    • With Each Diagnosis:
      • YouTube Video
      • Book from Library or Amazon
      • Support Group or Service
    • Tables for Patients:
      • Possible Special Education
      • Possible Social Security Disability Income
      • School Aid
    • Tables for Patients or Professionals
      • Overview of 9 Aspects of this Diagnosis
      • First Pages of Diagnoses from the Diagnostic and Statistical Manual and the Codes from the ICD-10 for Diagnosis and Compensation
  • Medical & Educational Downloads
  • Contact Us
Select Page

Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG

by jlohrconsulting | Aug 8, 2025 | Uncategorized

Front Immunol. 2025 Jul 24;16:1610486. doi: 10.3389/fimmu.2025.1610486. eCollection 2025. ABSTRACT BACKGROUND: Glial fibrillary acidic protein-immunoglobulin G (GFAP-IgG) can coexist with aquaporin-4-IgG (AQP4-IgG) or myelin oligodendrocyte glycoprotein-IgG (MOG-IgG)....

First trimester antidepressant use and miscarriage: a comprehensive analysis in the Clinical Practice Research Datalink GOLD

by jlohrconsulting | Aug 8, 2025 | Uncategorized

Br J Gen Pract. 2025 Aug 7:BJGP.2025.0092. doi: 10.3399/BJGP.2025.0092. Online ahead of print. ABSTRACT Background Antidepressant prescribing during pregnancy is rising but uncertainties remain surrounding safety. Evidence relating to antidepressant use during...

Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles

by jlohrconsulting | Aug 8, 2025 | Uncategorized

Sci Rep. 2025 Aug 7;15(1):28919. doi: 10.1038/s41598-025-14385-2. ABSTRACT Viloxazine and dextroamphetamine as newly approved drugs for the medical treatment of Attention Deficit Hyperactivity Disorder (ADHD) in recent years give new options for the treating of...

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system

by jlohrconsulting | Aug 8, 2025 | Uncategorized

Sci Rep. 2025 Aug 7;15(1):28886. doi: 10.1038/s41598-025-13786-7. ABSTRACT Vortioxetine is an antidepressant approved for the treatment of major depressive disorder (MDD). Given its widespread post-marketing clinical use, it is essential to explore its real-world...

Effects of bariatric surgery upon the sympathetic nervous system and hypothalamic-pituitary-adrenal axis in obese humans

by jlohrconsulting | Aug 8, 2025 | Uncategorized

Sci Rep. 2025 Aug 7;15(1):28916. doi: 10.1038/s41598-025-14537-4. ABSTRACT Human obesity is a state of hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and dysfunction of the sympathetic nervous system (SNS). It is unclear whether weight loss will...

Disentangling large-scale brain dynamics and their links to behavior during the emotional face matching task

by jlohrconsulting | Aug 8, 2025 | Uncategorized

Commun Biol. 2025 Aug 7;8(1):1176. doi: 10.1038/s42003-025-08543-5. ABSTRACT Emotion processing engages multiple large-scale brain networks. However, prior investigations relying on a priori, contrast-based models of brain activity obscure networks’ distinct...
« Older Entries
Next Entries »

Recent Posts

  • Dissociative Drug-Induced Anxiety
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)

Recent Comments